cynapsus therapeutics  wikipedia cynapsus therapeutics from wikipedia the free encyclopedia   redirected from cynapsus therapeutics inc jump to navigation search cynapsus therapeutics inc type subsidiary traded as tsx cth nasdaq cyna industry pharmaceuticals founded  headquarters marlborough massachusetts united states parent sunovion website httpwwwsunovioncom cynapsus therapeutics inc is a specialty pharmaceutical company developing a drug to treat the motor symptoms of parkinson’s disease based in toronto ontario canada formerly named cannasat therapeutics they changed their name to cynapsus therapeutics in  in september  sunovion a subsidiary of dainippon sumitomo pharma announced it would acquire cynapsus therapeutics for approximately  million contents  company overview  products  apl  external links  references company overviewedit cynapsus is a specialty pharmaceutical company developing the only oral sublingual delivery of the only approved drug apomorphine to treat the motor symptoms of parkinson’s disease over one million people in the united states and an estimated  million people globally suffer from parkinsons disease parkinson’s disease is a chronic and progressive neurodegenerative disease that impacts motor activity and its prevalence is increasing with the aging of the population based on the impact registry study and the results of cynapsus’ global  neurologists survey it is estimated that between  percent and  percent of patients experience “off” episodes in which they have impaired movement or speaking capabilities current medications only control the disease’s symptoms and most drugs become less effective over time as the disease progresses cynapsus’ lead drug candidate apl is an easytoadminister fastacting and oral reformulation of an approved drug apomorphine used to rescue patients from “off” episodes cynapsus is focused on rapidly maximizing the value of apl by completing pivotal studies in advance of a new drug application expected to be submitted in  cynapsus anticipates outlicensing to an appropriate pharmaceutical partner before such an application is submitted productsedit apledit apl is a reformulation of an approved parkinson’s drug apl is a novel oral formulation of an approved drug for parkinson‘s patients designed to deliver significant clinical benefits over the current marketed treatment the drug will treat patients with moderate to severe pd and address a significant unmet clinical need as expressed by clinicians and patients the drug is expected to undergo accelerated approval through b fda regulatory pathway with the us fda and a similar pathway with other international regulatory agencies this well developed regulatory path could result in a new drug approval application being submitted in late  or early  apl has the potential to address a significant underserved portion of  billion parkinson’s disease market cynapsus has entered into an agreement with adagio pharmaceuticals ltd granting cynapsus the option to execute a proposed exclusive worldwide agreement to license all intellectual property relating to and issued from continuing development apl external linksedit official website biofinance  company overview referencesedit  httpwwwmarketwirecompressreleasecannasatchangesnametocynapsustherapeuticstsxventurecthhtm  sunovion to acquire cynapsus for m  gen news highlights  gen  retrieved from httpsenwikipediaorgwindexphptitlecynapsustherapeuticsoldid categories companies listed on the toronto stock exchangepharmaceutical companies of canadacompanies based in toronto navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  november  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view cynapsus therapeutics  wikipedia cynapsus therapeutics from wikipedia the free encyclopedia   redirected from cynapsus therapeutics inc jump to navigation search cynapsus therapeutics inc type subsidiary traded as tsx cth nasdaq cyna industry pharmaceuticals founded  headquarters marlborough massachusetts united states parent sunovion website httpwwwsunovioncom cynapsus therapeutics inc is a specialty pharmaceutical company developing a drug to treat the motor symptoms of parkinson’s disease based in toronto ontario canada formerly named cannasat therapeutics they changed their name to cynapsus therapeutics in  in september  sunovion a subsidiary of dainippon sumitomo pharma announced it would acquire cynapsus therapeutics for approximately  million contents  company overview  products  apl  external links  references company overviewedit cynapsus is a specialty pharmaceutical company developing the only oral sublingual delivery of the only approved drug apomorphine to treat the motor symptoms of parkinson’s disease over one million people in the united states and an estimated  million people globally suffer from parkinsons disease parkinson’s disease is a chronic and progressive neurodegenerative disease that impacts motor activity and its prevalence is increasing with the aging of the population based on the impact registry study and the results of cynapsus’ global  neurologists survey it is estimated that between  percent and  percent of patients experience “off” episodes in which they have impaired movement or speaking capabilities current medications only control the disease’s symptoms and most drugs become less effective over time as the disease progresses cynapsus’ lead drug candidate apl is an easytoadminister fastacting and oral reformulation of an approved drug apomorphine used to rescue patients from “off” episodes cynapsus is focused on rapidly maximizing the value of apl by completing pivotal studies in advance of a new drug application expected to be submitted in  cynapsus anticipates outlicensing to an appropriate pharmaceutical partner before such an application is submitted productsedit apledit apl is a reformulation of an approved parkinson’s drug apl is a novel oral formulation of an approved drug for parkinson‘s patients designed to deliver significant clinical benefits over the current marketed treatment the drug will treat patients with moderate to severe pd and address a significant unmet clinical need as expressed by clinicians and patients the drug is expected to undergo accelerated approval through b fda regulatory pathway with the us fda and a similar pathway with other international regulatory agencies this well developed regulatory path could result in a new drug approval application being submitted in late  or early  apl has the potential to address a significant underserved portion of  billion parkinson’s disease market cynapsus has entered into an agreement with adagio pharmaceuticals ltd granting cynapsus the option to execute a proposed exclusive worldwide agreement to license all intellectual property relating to and issued from continuing development apl external linksedit official website biofinance  company overview referencesedit  httpwwwmarketwirecompressreleasecannasatchangesnametocynapsustherapeuticstsxventurecthhtm  sunovion to acquire cynapsus for m  gen news highlights  gen  retrieved from httpsenwikipediaorgwindexphptitlecynapsustherapeuticsoldid categories companies listed on the toronto stock exchangepharmaceutical companies of canadacompanies based in toronto navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  november  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view cynapsus therapeutics  wikipedia cynapsus therapeutics from wikipedia the free encyclopedia   redirected from cynapsus therapeutics inc jump to navigation search cynapsus therapeutics inc type subsidiary traded as tsx cth nasdaq cyna industry pharmaceuticals founded  headquarters marlborough massachusetts united states parent sunovion website httpwwwsunovioncom cynapsus therapeutics inc is a specialty pharmaceutical company developing a drug to treat the motor symptoms of parkinson’s disease based in toronto ontario canada formerly named cannasat therapeutics they changed their name to cynapsus therapeutics in  in september  sunovion a subsidiary of dainippon sumitomo pharma announced it would acquire cynapsus therapeutics for approximately  million contents  company overview  products  apl  external links  references company overviewedit cynapsus is a specialty pharmaceutical company developing the only oral sublingual delivery of the only approved drug apomorphine to treat the motor symptoms of parkinson’s disease over one million people in the united states and an estimated  million people globally suffer from parkinsons disease parkinson’s disease is a chronic and progressive neurodegenerative disease that impacts motor activity and its prevalence is increasing with the aging of the population based on the impact registry study and the results of cynapsus’ global  neurologists survey it is estimated that between  percent and  percent of patients experience “off” episodes in which they have impaired movement or speaking capabilities current medications only control the disease’s symptoms and most drugs become less effective over time as the disease progresses cynapsus’ lead drug candidate apl is an easytoadminister fastacting and oral reformulation of an approved drug apomorphine used to rescue patients from “off” episodes cynapsus is focused on rapidly maximizing the value of apl by completing pivotal studies in advance of a new drug application expected to be submitted in  cynapsus anticipates outlicensing to an appropriate pharmaceutical partner before such an application is submitted productsedit apledit apl is a reformulation of an approved parkinson’s drug apl is a novel oral formulation of an approved drug for parkinson‘s patients designed to deliver significant clinical benefits over the current marketed treatment the drug will treat patients with moderate to severe pd and address a significant unmet clinical need as expressed by clinicians and patients the drug is expected to undergo accelerated approval through b fda regulatory pathway with the us fda and a similar pathway with other international regulatory agencies this well developed regulatory path could result in a new drug approval application being submitted in late  or early  apl has the potential to address a significant underserved portion of  billion parkinson’s disease market cynapsus has entered into an agreement with adagio pharmaceuticals ltd granting cynapsus the option to execute a proposed exclusive worldwide agreement to license all intellectual property relating to and issued from continuing development apl external linksedit official website biofinance  company overview referencesedit  httpwwwmarketwirecompressreleasecannasatchangesnametocynapsustherapeuticstsxventurecthhtm  sunovion to acquire cynapsus for m  gen news highlights  gen  retrieved from httpsenwikipediaorgwindexphptitlecynapsustherapeuticsoldid categories companies listed on the toronto stock exchangepharmaceutical companies of canadacompanies based in toronto navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  november  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sunovion pharmaceuticals completes acquisition of cynapsus therapeutics  business wire sunovion pharmaceuticals completes acquisition of cynapsus therapeutics – sunovion expands and diversifies its neurology portfolio with addition of a latestage product candidate in development for off episodes associated with parkinson’s disease – download full size small preview thumbnail paginationprevious paginationnext full size small preview thumbnail full size small preview thumbnail october    am eastern daylight time marlborough mass  torontobusiness wiresunovion pharmaceuticals inc “sunovion” and cynapsus therapeutics inc “cynapsus” today announced that sunovion has completed through its wholly owned subsidiary sunovion cns development canada ulc the “purchaser” the previously announced acquisition of cynapsus the “acquisition” the acquisition is aligned with sunovion’s global strategy to expand and diversify its portfolio in key therapeutic areas including neurology sunovion intends to advance the clinical development program for a novel formulation of apomorphine “apl” which is a product candidate designed to be a fastacting easytouse sublingual thin film for the ondemand management of off episodes associated with parkinson’s disease “pd” “off episodes impair the ability to move and maintain normal activities and are often highly distressing to people with parkinson’s disease” said nobuhiko tamura chairman and chief executive officer sunovion “we look forward to the completion of the clinical development program for the sublingual formulation of apomorphine which if approved will be an important treatment option for off episodes associated with parkinson’s disease sunovion’s acquisition of cynapsus reinforces our vision to lead the way to a healthier world and our commitment to patients who are at the center of everything we do” beneficial holders of common shares “shares” and common share purchase warrants “warrants” of cynapsus are not required to take any action in respect of the closing of the acquisition as payment is expected to be credited to the beneficial holders’ intermediary accounts through established procedures beneficial securityholders should contact their intermediary if they have any questions regarding this process registered holders of cynapsus securities must submit certificates representing their securities and complete sign date and return the letter of transmittal sent to them with the other materials for the special meeting of cynapsus securityholders held on october   in order to receive the consideration to which they are entitled registered cynapsus securityholders who have not yet submitted the certificates for their securities and letters of transmittal are encouraged to do so as soon as possible any questions regarding payment of consideration for registered securityholders including any request for another copy of the letter of transmittal should be directed to tsx trust company via telephone at  toll free north america or via email at tmxeinvestorservicestmxcom in connection with the acquisition the purchaser acquired  shares and  warrants representing  of the outstanding shares and warrants respectively holders of shares received us or approximately cad in cash per share and holders of warrants received us or approximately cad in cash per warrant less the exercise price of such warrant the acquisition values cynapsus including all shares warrants and stock options of cynapsus at approximately us million or approximately cad million as a result of the acquisition cynapsus has become a whollyowned subsidiary of sunovion and the common shares of cynapsus will cease to be traded on the nasdaq stock market and toronto stock exchange the acquisition was completed by way of a plan of arrangement under the canada business corporations act the “arrangement” cynapsus will continue under the laws of the province of british columbia following which the purchaser cynapsus and a whollyowned subsidiary of cynapsus will amalgamate the “amalgamation” sunovion will be the sole shareholder of the amalgamated company to be named sunovion cns development canada ulc “amalco” following the amalgamation amalco will distribute substantially all of its assets to sunovion the shares are expected to be delisted from the nasdaq stock market and the toronto stock exchange in due course and sunovion and amalco intend to apply for cynapsus to cease to be a reporting issuer in addition as is customary following a transaction of this nature the directors of cynapsus resigned following the completion of the arrangement and were replaced by the then directors of the purchaser who will remain the directors of amalco about aplapl a novel formulation of apomorphine a dopamine agonist is being developed as a fastacting easytouse sublingual thin film for the ondemand management of debilitating off episodes associated with parkinson’s disease pd apomorphine is the only molecule approved for acute intermittent treatment of off episodes for advanced pd patients but in the united states is currently only approved as a subcutaneous injection apl is designed to rapidly safely and reliably convert a pd patient from the off to the on state while avoiding many of the issues associated with subcutaneous delivery of apomorphine it has been studied in all types of off episodes including morning off episodes apl is in phase  clinical trials and has not been approved by the us food and drug administration fda if the ongoing pivotal phase  clinical trials are successful it is expected that a new drug application nda for apl will be submitted to the us food and drug administration fda during the first half of fiscal year  under the abbreviated section b regulatory pathway about parkinson’s disease and off episodesmore than  million people in the us and an estimated  to  million people worldwide suffer from parkinson’s disease pd pd is a chronic progressive neurodegenerative disease characterized by motor symptoms including tremor at rest rigidity and impaired movement as well as significant nonmotor symptoms including cognitive impairment and mood disorders it is the second most common neurodegenerative disease behind alzheimer’s disease and pd’s prevalence is increasing with the aging of the population off episodes are a complication of the disease up to  percent of all people with pd whose symptoms are otherwise managed with ongoing drug therapy experience off episodes at least once daily and up to six times daily with each episode typically lasting between  and  minutesiii about sunovion pharmaceuticals inc sunovionsunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions sunovion’s vision is to lead the way to a healthier world the company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives with patients at the center of everything it does sunovion has charted new paths to lifetransforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric neurological and respiratory conditions sunovion’s track record of discovery development and commercialization of important therapies has included brovana® arformoterol tartrate latuda® lurasidone hci and most recently aptiom® eslicarbazepine acetate headquartered in marlborough mass sunovion is an indirect wholly owned subsidiary of sumitomo dainippon pharma co ltd sunovion pharmaceuticals europe ltd based in london england and sunovion pharmaceuticals canada inc based in mississauga ontario are whollyowned direct subsidiaries of sunovion pharmaceuticals inc additional information can be found on the company’s web sites wwwsunovioncom wwwsunovioneu and wwwsunovionca connect with sunovion on twitter linkedin facebook and youtube about sumitomo dainippon pharma co ltdsumitomo dainippon pharma is among the topten listed pharmaceutical companies in japan operating globally in major pharmaceutical markets including japan the united states china and the european union sumitomo dainippon pharma aims to create innovative pharmaceutical products in the psychiatry  neurology area and the oncology area which have been designated as the focus therapeutic areas sumitomo dainippon pharma is based on the merger in  between dainippon pharmaceutical co ltd and sumitomo pharmaceuticals co ltd today sumitomo dainippon pharma has about  employees worldwide additional information about sumitomo dainippon pharma is available through its corporate website at wwwdspharmacom brovana is a registered trademark of sunovion pharmaceuticals inclatuda is a registered trademark of sumitomo dainippon pharma co ltdaptiom is used under license from bial sunovion pharmaceuticals inc is a us subsidiary of sumitomo dainippon pharma co ltd   sunovion pharmaceuticals inc about the purchaserthe purchaser was formed for the purpose of completing the acquisition the purchaser’s address is  –  west georgia street vancouver british columbia vc l forwardlooking statementsthis press release includes forwardlooking statements within the meaning of the private securities litigation reform act of  that are subject to risks uncertainties and other factors all statements other than statements of historical fact are statements that could be deemed forwardlooking statements including all statements regarding the intent belief or current expectation of the companies’ and members of their senior management team forwardlooking statements include without limitation statements associated with the following sunovion’s ability to expand and diversify its portfolio in key therapeutic areas including neurology apl’s ability to be a fastacting easytouse ondemand treatment option for managing off episodes associated with parkinson’s disease pd sunovion’s ability to advance the clinical development program for apl and collaborate with the global parkinson’s disease community to address the significant need for new treatment options whether apl will be the first treatment for off episodes associated with pd that is administered sublingually under the tongue whether apl will avoid many of the issues associated with the currently available injectable formulation the timing of the data from the ongoing cynapsus pivotal phase  clinical trials and the potential success of the trials and the timing of a new drug application nda for apl if any to the us food and drug administration fda during the first half of fiscal year  under the abbreviated section b regulatory pathway investors are cautioned that any such forwardlooking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forwardlooking statements actual results may differ materially from those currently anticipated due to a number of risks and uncertainties risks and uncertainties that could cause the actual results to differ from expectations contemplated by forwardlooking statements include the effects of the transaction on relationships with employees customers other business partners or governmental entities other business effects including the effects of industry economic or political conditions outside of the companies control actual or contingent liabilities and other risks and uncertainties detailed by sunovion’s parent company sumitomo dainippon pharma in the summary of consolidated financial results japanese gaap unaudited for quarterly earnings all forwardlooking statements are based on information currently available to sunovion and sunovion assumes no obligation to update any such forwardlooking statements i denny  j neurolog sci v p table ii schrag  brain v p contacts sunovion pharmaceuticals incpatrick gaffey executive director corporate communicationspatrickgaffeysunovioncomorjennifer baird senior director corporate communicationsjenniferbairdsunovioncom release summary sunovion completes acquisition of cynapsus therapeutics expands neurology portfolio with latestage product candidate in development for off episodes associated with parkinsons disease contacts sunovion pharmaceuticals incpatrick gaffey executive director corporate communicationspatrickgaffeysunovioncomorjennifer baird senior director corporate communicationsjenniferbairdsunovioncom search advanced news search advanced news search log in sign up   flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising anthony giovinazzo cynapsus therapeutics inc profile  biography  bloomberg feedback anthony giovinazzo presidentceo cynapsus therapeutics inc career history presidentceo cynapsus therapeutics inc present presidentceo cannasat therapeutics inc  presidentceo gb therapeutics ltd former presidentceo prescient neuropharma inc former show more website wwwcynapsusca corporate information address  richmond street west toronto on mj c canada phone  fax  web url wwwcynapsusca from the web personal information education university of geneva mba  osgoode hall law school of york university  mcmaster university bachelors degree economics  show more memberships board memberships promis neurosciences inc board member present cynapsus therapeutics inc board member present majescor resources inc board member  show more sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     about cynapsus therapeutics inc cth  investingcom x breaking news how would you best describe yourself individual investor institutional investor financial advisor active trader thank you   search website for  popular searches trending stocks  stock screener  sign insign up  recent alerts sign up to create alerts for instruments economic events and content by followed authors sign up already have an account sign in english uktürkçeenglish india‏العربية‏english canadaελληνικάenglish australiasvenskaenglish south africasuomideutschעבריתespañol españaespañol méxico한국어françaisitalianonederlandsbahasa indonesiaportuguês portugalbahasa melayupolskiไทยportuguês brasiltiếng việtрусский cynapsus therapeutics inc cth   toronto create alert create alert new create alert website as an alert notification to use this feature make sure you are signedin to your account mobile app to use this feature make sure you are signedin to your account make sure you are signedin with the same user profile condition price change volume moves above moves below frequency once gains  loses gains loses  frequency recurring once volume exceeds frequency recurring once for all future releases just for the upcoming release send me a reminder  trading day before delivery method website popup mobile app notifications email notifications status create manage my alerts  back add toremove from a portfolio my portfolio add to watchlist add position position added successfully to please name your holdings portfolio type buy sell date   amount price point value leverage          commission   create a new watchlist create create a new holdings portfolio add create  add another position close         closed currency in cad  disclaimer  type equity market canada isin cay  cusip y volume  bidask    days range    start trading now cynapsus therapeutics inc    start trading now general     chart     streaming chart interactive chart news  analysis     news financials     financial summary income statement balance sheet cash flow ratios dividends earnings technical     technical analysis candlestick patterns consensus estimates forum     discussions recent sentiments user rankings overview profile historical data cynapsus therapeutics inc company profile   get an indepth profile of cynapsus therapeutics inc including a general overview of the companys business and key management as well as employee data and location and contact information industrybiotechnology  drugs sectorhealthcare employees equity typeord cynapsus therapeutics inc is a canadabased specialty central nervous system cns pharmaceutical company it develops a sublingual thin film for the potential treatment for ondemand management of debilitating off episodes associated with parkinson’s disease pd the company completed a phase two clinical trial for its product candidate apl a sublingual formulation of apomorphine hydrochloride or apomorphine apomorphine is the only molecule approved for acute intermittent treatment of off episodes for advanced pd patients but is currently only approved as a subcutaneous injection in the united states apl is a turning on medication designed to convert a pd patient from the off to the on state while avoiding the issues associated with subcutaneous delivery of apomorphine it is designed to convert all types of off episodes including morning off episodes furthermore the company has initiated its pivotal phase three clinical program for apl contact information address  richmond st wtoronto on mj ccanada phone  fax  web loading add a comment comment guidelines comment guidelines we encourage you to use comments to engage with users share your perspective and ask questions of authors and each other however in order to maintain the high level of discourse we’ve all come to value and expect please keep the following criteria in mind  enrich the conversation stay focused and on track only post material that’s relevant to the topic being discussed be respectful even negative opinions can be framed positively and diplomatically  use standard writing style include punctuation and upper and lower cases note spam andor promotional messages and links within a comment will be removed avoid profanity slander or personal attacks directed at an author or another user don’t monopolize the conversation we appreciate passion and conviction but we also believe strongly in giving everyone a chance to air their thoughts therefore in addition to civil interaction we expect commenters to offer their opinions succinctly and thoughtfully but not so repeatedly that others are annoyed or offended if we receive complaints about individuals who take over a thread or forum we reserve the right to ban them from the site without recourse only english comments will be allowed perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at investingcom’s discretion i have read investingcoms comments guidelines and agree to the terms described i agree   are you sure you want to delete this chart delete cancel     replace the attached chart with a new chart  replace cancel post post also to  please wait a minute before you try to comment again thanks for your comment please note that all comments are pending until approved by our moderators it may therefore take some time before it appears on our website  reply   show more comments  show more replies    are you sure you want to delete this chart delete cancel     replace the attached chart with a new chart  replace cancel post  please wait a minute before you try to comment again       report this comment i feel that this comment is spam offensive irrelevant submit comment flagged thank you your report has been sent to our moderators for review close add chart to comment cancel attach disclaimer fusion media would like to remind you that the data contained in this website is not necessarily realtime nor accurate all cfds stocks indexes futures and forex prices are not provided by exchanges but rather by market makers and so prices may not be accurate and may differ from the actual market price meaning prices are indicative and not appropriate for trading purposes therefore fusion media doesnt bear any responsibility for any trading losses you might incur as a result of using this data fusion media or anyone involved with fusion media will not accept any liability for loss or damage as a result of reliance on the information including data quotes charts and buysell signals contained within this website please be fully informed regarding the risks and costs associated with trading the financial markets it is one of the riskiest investment forms possible find a broker indices commodities forex bonds more categories tabs selectionindicescommoditiesforexbondsstocksetfscount selected applydwmmyymax sp  futures  nasdaq futures  dow   sp  vix  dax  nikkei   us dollar index  euro index  gold  silver  copper  crude oil wti  brent oil  natural gas  us cotton   us coffee c  eurusd  gbpusd  usdjpy  usdcad  audusd  usdcnh  ethusd  btcusd  us y yield  us y yield  us y yield  us y yield  us y tnote  us y tbond  euro bund  uk gilt  start trading today forexcommoditiesindicesstocks tabs selection forexcommoditiesindicesstocksbondsetfs count selected apply timeframe  min  mins  mins  mins hourly  hours daily weekly eurusd    summary strong buy moving averages buy  sell  indicators buy  sell  eurusd    summary strong buy moving averages buy  sell  indicators buy  sell  gbpusd    summary strong buy moving averages buy  sell  indicators buy  sell  usdjpy    summary strong sell moving averages buy  sell  indicators buy  sell  audusd    summary strong sell moving averages buy  sell  indicators buy  sell  usdcad    summary strong sell moving averages buy  sell  indicators buy  sell  eurjpy    summary strong buy moving averages buy  sell  indicators buy  sell  eurchf    summary strong buy moving averages buy  sell  indicators buy  sell  gold futures  summary moving averages buy sell indicators buy sell silver futures  summary moving averages buy sell indicators buy sell copper futures  summary moving averages buy sell indicators buy sell crude oil wti futures  summary moving averages buy sell indicators buy sell brent oil futures  summary moving averages buy sell indicators buy sell natural gas futures  summary moving averages buy sell indicators buy sell us coffee c futures  summary moving averages buy sell indicators buy sell dow jones industrial averag  summary moving averages buy sell indicators buy sell nasdaq   summary moving averages buy sell indicators buy sell sp   summary moving averages buy sell indicators buy sell dax  summary moving averages buy sell indicators buy sell ftse   summary moving averages buy sell indicators buy sell cac   summary moving averages buy sell indicators buy sell nikkei   summary moving averages buy sell indicators buy sell apple inc  summary moving averages buy sell indicators buy sell alphabet inc class a  summary moving averages buy sell indicators buy sell bank of america corp  summary moving averages buy sell indicators buy sell jpmorgan chase  co  summary moving averages buy sell indicators buy sell exxon mobil corporation  summary moving averages buy sell indicators buy sell bp plc  summary moving averages buy sell indicators buy sell deutsche bank ag na on  summary moving averages buy sell indicators buy sell us year  summary moving averages buy sell indicators buy sell us year  summary moving averages buy sell indicators buy sell us year  summary moving averages buy sell indicators buy sell us year  summary moving averages buy sell indicators buy sell euro bund futures  summary moving averages buy sell indicators buy sell us  year tnote futures  summary moving averages buy sell indicators buy sell japan government bond futur  summary moving averages buy sell indicators buy sell uk gilt futures  summary moving averages buy sell indicators buy sell spdr dow jones industrial a  summary moving averages buy sell indicators buy sell ishares russell  growth  summary moving averages buy sell indicators buy sell ishares russell   summary moving averages buy sell indicators buy sell powershares qqq trust serie  summary moving averages buy sell indicators buy sell spdr sp   summary moving averages buy sell indicators buy sell proshares ultrashort sp  summary moving averages buy sell indicators buy sell proshares ultrashort qqq  summary moving averages buy sell indicators buy sell     eurusd  strong buy       gbpusd  strong buy       usdjpy  strong sell       audusd  strong sell       usdcad  strong sell       eurjpy  strong buy       eurchf  strong buy       gold       silver       copper       crude oil wti       brent oil       natural gas       us coffee c       dow        nasdaq        sp        dax       ftse        cac        nikkei        apple       alphabet a       bank of america       jpmorgan       exxon mobil       bp       deutsche bank ag   start trading today recent quotes namepricechgchg   cth  add to watchlist add to watchlist add to watchlist max  select where to add the results added successfully create portfolio apply create close   market movers most active gainers  losers    name last chg  vol     fb   m     aapl   m     adp   m     baba   m     nvda   m     amzn   m     googl   m     name last chg  vol     adp   m     tdc   m     siri   m     tsco   m     vz   m     orly   m     kim   m     name last chg  vol     ca   m     jci   m     ffiv   m     xl   m     whr   m     psa   m     ivz   m   promotions should you try trading new markets nadex webinars identify sell and buy market areas tuesday august    pm edt does your trading edge suck lets fix it thursday august    pm edt intraday indicator pivot point daily formula tuesday august    pm edt neurolinguistics programming  trading psychology tuesday august    pm edt sign up for free and get realtime alerts advanced portfolio features personalized charts fullysynced app continue with facebook continue with google or sign up with email cth stock quote  cynapsus therapeutics inc  bloomberg markets error could not add to watchlist x  watchlist cynapsus therapeutics inc cthcn acquired cthcn was acquired by jp cad volume  before its here its on the bloomberg terminal learn more volume  current pe ratio ttm  earnings per share cad ttm  market cap cad  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later there are currently no press releases for this ticker please check back later profile cynapsus therapeutics inc operates as a pharmaceutical company the company focuses on developing a sublingual thin film strip for the acute rescue of off motor symptoms of parkinsons disease address  richmond street westtoronto on mj ccanada phone  website wwwcynapsusca executives board members anthony j giovinazzo presidentceo andrew michael williams cfocoosecretary albert agro chief medical ofcrcofounder thierry bilbault exec vpcmcchief scientific ofcr kristen galfetti vpinvestor relations show more cynapsus pharmaceuticals  overdrive design ltd home work about contact overdrive is a full service communications branding and interactive agency our business is to solve brand and communications challenges for other organizations and to impact the business operations of those organziations in an appreciable and positive way address  hook avenue suite  toronto ontario mp t canada contact phone    email infooverdrivedesigncom social facebook twitter pinterest behance linkedin vimeo cynapsuspharmaceuticals a parkinsons company details  category web design  project cynapsus web redesign  client cynapsus therapeutics inc restoring movement with ease  description overdrive was commissioned to rebrand cynapsus therapeutics in  including collateral and website overdrive was then engaged again in  for a brand strategy exercise and rebuild of the older site with the client’s signature pharmaceutical property for treating parkinson’s disease symptoms moving closer towards commercialization the outcomes of the brand strategy exercise indicated a focus on three main interest groups  patients professional practitioners and investors this approach would be changed many times in the completion of the website which was launched in early  but the overall design remained largely intact the goal was to create a website with multiple sections tracked to different site user demographics each section containing easily digestible content written in a lightaccessible tone deeper content is available in an archive of press releases and technical scientific documents hosted in a site database visually the centrepiece of the site are a series of fullscreen looping videos created with award winning cinematography iris ng these are featured on the site’s landing page and are intended to illustrate the benefit of cynapsus’ product to a typically older end user  that being the relief of freezing episodes and restoring physical movement for everyday activities  deliverables brand strategy website full motion video  credits overdrive design limited concept and creative web design user interface web development project management video castingart directionproduction laila zichmanis lumena – brand management brand strategy iris ng video footage lighting camera work etc  links visit the cynapsus website httpwwwcynapsusca note the live investors section on the current site is based on studies provided by overdrive but is executed by a third party overdrive neither art directed or project managed that section of the site and therefore is not responsible for the outcome of the end product  more info cynapsus the cynapsus logo is based on the notion of synapses in our brains synapses are the spaces in between neurons that pass electrial signals in the case of the logo the horizontal breaks in individual letterforms represent synapses while aligning them across letterforms represents a network  more info charts an assortment of chart field and icon styles used on the site  sunovion pharmaceuticals to acquire cynapsus therapeuticshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  hrs  minssp futures dow futures nasdaq futures sunovion pharmaceuticals to acquire cynapsus therapeuticsbusiness wireaugust  reblogsharetweetsharesunovion pharmaceuticals to acquire cynapsus therapeuticsmoremarlborough mass  torontobusiness wiresunovion pharmaceuticals inc sunovion and cynapsus therapeutics inc cynapsus cyna cthto today announced that the companies have signed a definitive agreement under which sunovion will acquire cynapsus for us per share in cash the transaction has received unanimous approval by the board of directors of both companies and values cynapsus at approximately us million or approximately can million the acquisition will be funded with cash on hand the transaction is expected to close in the fourth quarter of  third quarter of sunovion’s fiscal year this agreement reflects sunovion’s global strategy to expand and diversify its portfolio in key therapeutic areas including neurologythis smart news release features multimedia view the full release here httpwwwbusinesswirecomnewshomeen through this transaction sunovion would acquire cynapsus’ product candidate apl which is designed to be a fastacting easytouse ondemand treatment option for managing off episodes associated with parkinson’s disease pd“parkinson’s disease is a chronic progressive neurodegenerative disease that affects more than four million people around the world and there is a significant need for new options to treat the off episodes associated with it” said nobuhiko tamura chairman and chief executive officer sunovion “we believe that apl is a novel latestage candidate with the potential to make a real difference for patients and their families”“the acquisition of cynapsus is wellaligned with sunovion’s focus on the innovative application of science and medicine to help people with serious medical conditions and complements our robust product pipeline” added mr tamura “we have high regard for the cynapsus team and their work with the apl program”“with its leadership in therapies for central nervous system disorders and commercial experience specific to neurology we believe sunovion is best suited to advance apl in the united states and other key markets” said anthony j giovinazzo president and ceo cynapsus “this transaction culminates years of dedicated work by the cynapsus team and represents significant value creation for our securityholders”the board of directors of cynapsus after consultation with its financial and legal advisors and based in part upon the unanimous recommendation of an independent special committee of the board of directors has determined that the arrangement is in the best interest of cynapsus and the consideration to be received by shareholders of cynapsus is fair to such shareholders the board of directors unanimously recommends that cynapsus shareholders and warrantholders vote in favour of the transaction at a special meeting expected to be held on or about october  the proposed sale of cynapsus follows a full consideration of alternatives aimed at optimizing shareholder value for the company “we believe that the proposed transaction with sunovion results in the best outcome for our shareholders” said rochelle stenzler chair of the board of cynapsus “the transaction with sunovion represents a significant premium to the current share price and we are recommending that our shareholders and warrantholders vote in favour of the transaction”pursuant to the terms of the definitive agreement upon closing of the proposed transaction shareholders of cynapsus will receive us per common share in cash and holders of warrants and stock options will receive a cash payment equal to the difference between us and the exercise price of such warrant or stock option the offer of us per common share in cash represents a premium of  percent based on the volume weighted average closing price of cynapsus’ common shares on the nasdaq global market for the last twenty trading days the companies expect to close the transaction following required securityholder court and regulatory approvals and satisfaction of certain other customary closing conditionsthe transaction will be completed by way of a plan of arrangement under the canada business corporations act the arrangement will require approval of at least twothirds of the votes cast by cynapsus shareholders and warrantholders voting together as a single class at a special meeting of such securityholders of cynapsus voting and support agreements in support of the transaction have been signed by all directors and officers of cynapsus and the company’s largest shareholder representing in the aggregate approximately  percent of the cynapsus securities entitled to vote to approve the transactionread morefull details of the transaction will be included in the management information circular to be filed with the applicable securities regulatory authorities and mailed to cynapsus shareholders and warrant holders within approximately two weeks assuming receipt of all required regulatory approvals the parties expect to close the arrangement in the fourth quarter of bofa merrill lynch serves as financial advisor and borden ladner gervais llp and troutman sanders llp serve as legal advisors to cynapsus stifel nicolaus  company incorporated serves as financial advisor and fasken martineau dumoulin llp serves as a legal advisor to the special committee of cynapsus nomura securities international inc serves as exclusive financial advisor and goodmans llp reed smith llp and gibbons pc serve as legal advisors to sunovionadagio amending agreementcynapsus and the former shareholders of adagio pharmaceuticals ltd “adagio” entered into a share purchase agreement dated as of december   as subsequently amended as of january   the “share purchase agreement” pursuant to which cynapsus acquired adagiocynapsus and the former shareholders of adagio have amended the share purchase agreement to provide among other things that if a change of control of cynapsus which would include the transaction with sunovion occurs before the successful completion and the first public announcement of the topline data of the final safety study as defined in the share purchase agreement the cdn of the purchase price still potentially payable to the former shareholders of adagio shall be paid in cash not common shares as was originally contemplated in the share purchase agreement by cynapsus on the date on which the change of control transaction is completedas anthony giovinazzo president and chief executive officer of cynapsus is also a director officer and majority shareholder of adagio the amendment of the share purchase agreement constitutes a related party transaction pursuant to multilateral instrument  and the policies of the tsx the amendment was necessary and appropriate as it ensures that if sunovion acquires all of the common shares of cynapsus it would not have an obligation to potentially issue shares to the former adagio shareholders postclosing of such acquisition the amendment was entered into at the same time as the arrangement agreement with sunovion and therefore was not announced more than  days before its executionabout aplapl a novel formulation of apomorphine a dopamine agonist is being developed as a fastacting easytouse sublingual thin film for the ondemand management of debilitating off episodes associated with parkinson’s disease apomorphine is the only molecule approved for acute intermittent treatment of off episodes for advanced pd patients but is currently only approved as a subcutaneous injection in the united states apl is designed to rapidly safely and reliably convert a pd patient from the off to the on state while avoiding many of the issues associated with subcutaneous delivery of apomorphine it has been studied in all types of off episodes including morning off episodes apl is in phase  clinical trials and has not been approved by the us food and drug administration fdain the ongoing phase  trial cth the blinded safety data was corroborated by the dsmb findings which were announced in the press release dated august   if the ongoing pivotal phase  clinical trials are successful it is expected that a new drug application nda for apl will be submitted to the us food and drug administration fda during the first half of  under the abbreviated section b regulatory pathway a pivotal european clinical program evaluating the safety and efficacy of apl in pd patients is expected to be initiated in the fourth quarter of about parkinson’s disease and off episodesmore than  million people in the us and an estimated  to  million people worldwide suffer from pd the european parkinsons disease association estimates that  million people have pd in the european union pd is a chronic progressive neurodegenerative disease characterized by motor symptoms including tremor at rest rigidity and impaired movement as well as significant nonmotor symptoms including cognitive impairment and mood disorders it is the second most common neurodegenerative disease behind alzheimer’s disease and pd’s prevalence is increasing with the aging of the population off episodes are a complication of the disease up to  percent of all people with pd whose symptoms are otherwise managed with ongoing drug therapy experience off episodes at least once daily and up to six times daily with each episode typically lasting between  and  minutesabout sunovion pharmaceuticals inc sunovionsunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives the company has charted new paths to lifetransforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric neurological and respiratory conditions sunovion’s track record of discovery development and commercialization of important therapies has included brovana® arformoterol tartrate latuda® lurasidone hci and most recently aptiom® eslicarbazepine acetateheadquartered in marlborough mass sunovion is an indirect wholly owned subsidiary of sumitomo dainippon pharma co ltd sunovion pharmaceuticals europe ltd based in london england and sunovion pharmaceuticals canada inc based in mississauga ontario are whollyowned direct subsidiaries of sunovion pharmaceuticals inc additional information can be found on the company’s web sites wwwsunovioncom wwwsunovioneu and wwwsunovionca connect with sunovion on twitter sunovion and linkedinabout sumitomo dainippon pharma co ltdsumitomo dainippon pharma is among the topten listed pharmaceutical companies in japan operating globally in major pharmaceutical markets including japan the united states china and the european union sumitomo dainippon pharma aims to create innovative pharmaceutical products in the psychiatry  neurology area and the oncology area which have been designated as the focus therapeutic areas sumitomo dainippon pharma is based on the merger in  between dainippon pharmaceutical co ltd and sumitomo pharmaceuticals co ltd today sumitomo dainippon pharma has about  employees worldwide additional information about sumitomo dainippon pharma is available through its corporate website at wwwdspharmacombrovana is a registered trademark of sunovion pharmaceuticals inclatuda is a registered trademark of sumitomo dainippon pharma co ltdaptiom is used under license from bialsunovion pharmaceuticals inc is a us subsidiary of sumitomo dainippon pharma co ltd  sunovion pharmaceuticals incsunovion forwardlooking statementthis press release includes forwardlooking statements within the meaning of the private securities litigation reform act of  that are subject to risks uncertainties and other factors all statements other than statements of historical fact are statements that could be deemed forwardlooking statements including all statements regarding the intent belief or current expectation of the companies and members of their senior management team forwardlooking statements include without limitation statement associated with the following the timing of the closing of sunovion’s acquisition of cynapsus sunovion’s ability to expand and diversify its portfolio in key therapeutic areas including neurology apl’s ability to be a fastacting easytouse ondemand treatment option for managing off episodes associated with parkinson’s disease pd or make a real difference for patients and their families sunovion’s ability to advance apl in the united states and other key markets whether the transaction will result in the best outcome for cynapsus’ shareholders the parties’ ability to receive the required securityholder court and regulatory approvals satisfy other customary closing conditions and close the transaction whether apl will be the first treatment for off episodes associated with pd that is administered sublingually under the tongue whether apl will avoid many of the issues associated with the currently available injectable formulation whether apl will be easier for patients and caregivers to use the timing of the data from the ongoing cynapsus pivotal phase  clinical trials the potential success of the trials and the timing of a new drug application nda for apl if any to the us food and drug administration fda during the first half of  under the abbreviated section b regulatory pathway the timing of a pivotal european clinical program evaluating the safety and efficacy of apl in pd patients the timing and content of the details of the transaction included in the management information circular to be filed with the securities regulatory authorities and mailed to cynapsus shareholders and warrant holders in advance of the special meeting the ability to receive all required regulatory approvals and the ability of the parties to close the arrangement in the fourth quarter of  investors are cautioned that any such forwardlooking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forwardlooking statements actual results may differ materially from those currently anticipated due to a number of risks and uncertainties risks and uncertainties that could cause the actual results to differ from expectations contemplated by forwardlooking statements include the effects of the transaction on relationships with employees customers other business partners or governmental entities other business effects including the effects of industry economic or political conditions outside of the companies control actual or contingent liabilities and other risks and uncertainties detailed by sunovion’s parent company sumitomo dainippon pharma in the summary of consolidated financial results japanese gaap unaudited for quarterly earnings all forwardlooking statements are based on information currently available to sunovion and sunovion assumes no obligation to update any such forwardlooking statementsabout cynapsuscynapsus is a specialty central nervous system pharmaceutical company that has been developing a fastacting easytouse sublingual thin film for the ondemand management of debilitating off episodes associated with pd for additional company information please visit httpwwwcynapsuscafor more information about the phase  studies including enrollment criteria please visit the following website httpcthandtrialscynapsuscacynapsus forwardlooking statementsthis press release contains “forwardlooking statements” within the meaning of applicable securities laws including without limitation cynapsus’s expectation for filing an nda in the first half of  expectations regarding cynapsus’s clinical and regulatory activities including the anticipated timing completion and results of phase  and other clinical studies beliefs related to potential benefits effectiveness and demand for cynapsus’s product candidate statements relating to the proposed acquisition of cynapsus including i receipt of securityholder court and regulatory approvals of and the satisfaction of other conditions for such transaction and ii the anticipated benefits timing and closing of such transaction and beliefs regarding sunovion’s ability to advance apl in the united states and other markets these forwardlooking statements include information about possible or assumed future events or results of cynapsus’s business products plans and objectives these forwardlooking statements are based on current expectations and beliefs and inherently involve significant risks and uncertainties actual results and the timing of events could differ from those anticipated in such forwardlooking statements as a result of risks and uncertainties and include but are not limited to shareholder and warrantholder approval of the proposed transaction cynapsus’ ability to obtain court regulatory and other approvals in connection with the proposed transaction uncertainties as to the timing of the completion of the transaction including that a governmental entity may prohibit delay or refuse to grant approval for the consummation of the transaction and those factors identified under the caption “risk factors” in cynapsus’s form q for the quarter ended june   filed with the united states securities and exchange commission the “sec” on august   and its other filings and reports in the united states with the sec available on the sec’s web site at wwwsecgov and in canada with the various canadian securities regulators which are available online at wwwsedarcom furthermore unless otherwise stated the forwardlooking statements contained in this press release are made as of the date of this press release and cynapsus has no intention and undertakes no obligation to update or revise any forwardlooking statements whether as a result of new information future events changes or otherwise except as required by lawadditional information and where to find itfurther information regarding the transaction will be contained in an information circular that cynapsus will prepare and mail to its shareholders and warrantholders in connection with the cynapsus shareholders’ and warrantholders’ meeting with closing expected to occur in the fourth quarter of  cynapsus securityholders are urged to read the information circular once it becomes available as it will contain important information concerning the proposed transaction cynapsus securityholders may obtain a copy of the arrangement agreement information circular and other meeting materials when they become available at httpwwwsecgov and wwwsedarcomthis press release is for informational purposes only it does not constitute an offer to purchase securities of cynapsus or a solicitation or recommendation statement under the rules and regulations of the sec or other applicable united states laws denny  j neurolog sci v p table  schrag  brain v pview source version on businesswirecom httpwwwbusinesswirecomnewshomeenmultimedia availablehttpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nexthypothetically speaking us admiral says ready for nuclear strike on china if trump so orderedreuterszuckerberg wifes ambitious secret finally exposedunewzmesponsored​​ncis scores maria bello as new series regular for season entertainment tonightscaramucci threats insults inflame fierce white house fightassociated pressgrandmother lays in pool of blood playing dead after being attacked night before her husbands funeralthe independentthis will be in everyones household by banyan hillsponsoredmicrosoft confirms windows  has seriously nasty surpriseforbessean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insidertrump’s unwitting legacy could be universal health coverageyahoo financeengineer finds pattern makes millions in stocksmoney morningsponsoredrepublicans kill the border taxyahoo financetwitter is only famous now because of president trump nyse traderyahoo finance videogdp — what you need to know in markets on fridayyahoo financewomen need to carry this device with themsiren songsponsoredwhite house comms director scaramucci im not steve bannon im not trying to suck my own ckbusiness insidermattis was on vacation when trump tweeted transgender ban and he was reportedly appalled by itbusiness insidereu warns us it may respond swiftly to counter new sanctions on russiabiafra republic us is only trying to control the world alone without competition or disturbancesjoin the conversation   ﻿ sunovion  sunovion – home page sunovion close video lead the way to a healthier world by putting patients at the center of everything we do we are focused on developing innovative therapies and transforming the lives of people with serious medical conditions watch video helping people with serious medical conditions lead fulfilling lives building on a track record of discovery development and commercialization of important therapies we have a robust and growing portfolio of treatments to address serious psychiatric neurological and respiratory conditions explore our pipeline our therapies find out how we are addressing serious psychiatric conditions we are investigating novel treatments to psychiatric disorders that will help people with these conditions live better lives take a look at our areas of psychiatric research discover what were doing to investigate serious neurological conditions we are engaged in the quest for treatment paths that will improve the lives of millions impacted by neurologic conditions review the focus of our neurological research explore our research in serious respiratory conditions we strive to advance the science of medicine for respiratory conditions see where we are concentrating our respiratory research featured news most recent july   sunovion’s latuda® lurasidone hci receives health canada approval to treat adolescents with schizophrenia read our announcement july   sunovion expands commitment to building stronger communities through partnerships with the red sox foundation united way of tricounty and bergen volunteer center read our announcement july   sunovion enters agreement to divest asthma and allergy products to covis pharma read our announcement our people share a passion to make a difference our commitment supporting patient advocacy in our communities we partner with leading patient advocacy organizations and participate in a wide variety of events that help to raise awareness and support educational and research programs sunovion by the numbers ndfastestgrowing pharmaceutical company in the us employees worldwide employee volunteer hours in  years see how we make a difference hands on learn more about sunovion’s annual day of community service page sources